Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Otolaryngology (Ear, Nose, Throat) | Family Medicine
Head and Neck Cancer Clinical Trials
A listing of Head and Neck Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
California
Duarte : City of Hope
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Monterey : Monterey Bay Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Oxnard : Ventura County Hematology Oncology Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Stanford :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Stanford : Stanford University School of Medicine
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Stanford : Stanford Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Colorado
Aurora : University of Colorado Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Aurora :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Aurora : University of Colorado Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
District of Columbia
Washington : George Washington University - Medical Faculty Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Florida
Jacksonville : Integrated Community Oncology Network
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Miami : Advanced Medical Specialties
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New Port Richey : Pasco Pinellas Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Miami :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Georgia
Atlanta : Peachtree Hematology and Oncology Consultants, PC
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Savannah : Memorial University Medical Center
ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
Savannah : Memorial University Medical Center
RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.
Savannah : Memorial University Medical Center
RTOG 1016. Phase III Trial of Radiotherapy plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer.
Illinois
Elgin : Sherman Health
ECOG E1305 A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer
Elgin : Sherman Health
RETAIN: Resistance Training and Physical Functioning in Patients with Head & Neck Cancer
View More »
Chicago :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Chicago : The University of Chicago Medical Center Updated
Everolimus Versus Placebo in Head and Neck Cancer
Chicago : University of Illinois-Chicago Updated
Everolimus Versus Placebo in Head and Neck Cancer
Chicago : Northwestern University Updated
Everolimus Versus Placebo in Head and Neck Cancer
Chicago : The University of Chicago Medical Center
Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Harvey : Ingalls Cancer Research Center Updated
Everolimus Versus Placebo in Head and Neck Cancer
Kansas
Kansas City : University of Kansas Updated
Everolimus Versus Placebo in Head and Neck Cancer
Kentucky
Paducah :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Louisiana
Shreveport : Louisianna State University Updated
Everolimus Versus Placebo in Head and Neck Cancer
Shreveport : Overton Brooks VA Medical Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Maryland
Bethesda : Center for Cancer and Blood Disorders
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Baltimore : Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC
Baltimore :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Massachusetts
Boston :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Boston : Tufts Medical Center Updated
Everolimus Versus Placebo in Head and Neck Cancer
Boston : Massachusetts General Hospital
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Michigan
Ann Arbor : University of Michigan
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Ann Arbor : University of Michigan Updated
Everolimus Versus Placebo in Head and Neck Cancer
Detroit : Henry Ford Health System
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Minnesota
Minneapolis : University of Minnesota Updated
Everolimus Versus Placebo in Head and Neck Cancer
Mississippi
Tupelo : North Mississippi Health Services
Squamous Cell Carcinoma
View More »
Jackson : University of Mississippi Updated
Everolimus Versus Placebo in Head and Neck Cancer
Missouri
Bridgeton : Saint Louis Cancer Care LLP
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
St Joseph :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
St. Louis : Washington University Updated
Everolimus Versus Placebo in Head and Neck Cancer
New Jersey
East Orange : NJ Medical School VA NJ Healthcare
Squamous Cell Carcinoma
View More »
Basking Ridge : Memorial Sloan-Kettering Cancer Center at Basking Ridge
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Basking Ridge : Memorial Sloan-Kettering Cancer Center at Basking Ridge
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
New York
Manhasset : Biomedical Research Alliance of New York
Head and Neck Cancer - Adults
View More »
Commack : Memorial Sloan-Kettering Cancer Center at Commack
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
New York : Memorial Sloan Kettering Cancer Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
New York : Memorial Sloan Kettering Cancer Center
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
New York : Memorial Sloan Kettering Cancer Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
North Carolina
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chapel Hill : University of North Carolina Updated
Everolimus Versus Placebo in Head and Neck Cancer
Chapel Hill : University of North Carolina at Chapel Hill
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Chapel Hill : The University of North Carolina at Chapel Hill
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Ohio
Columbus : Ohio State University Medical Center
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC
Columbus : Ohio State University Updated
Everolimus Versus Placebo in Head and Neck Cancer
Pennsylvania
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Philadelphia : Fox Chase Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Philadelphia : Thomas Jefferson University
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Pittsburgh : University of Pittsburgh Cancer Institute
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
South Carolina
Charleston :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Charleston : Medical University of South Carolina Hollings Cancer Center Updated
Everolimus Versus Placebo in Head and Neck Cancer
Tennessee
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Knoxville :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Nashville : Vanderbilt University Updated
Everolimus Versus Placebo in Head and Neck Cancer
Nashville : Vanderbilt University
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Nashville : Vanderbilt-Ingram Cancer Center
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Texas
Virginia
Newport News : Peninsula Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Washington
Seattle : University of Washington- Seattle Cancer Care Alliance
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG1305 - A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
RTOG-0920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
RTOG-1016 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Australia
Kurralta Park :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Canada
Barrie : Royal Victoria Regional Health Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Edmonton : Cross Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Greenfield Park : Hôpital Charles-LeMoyne
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Laval : Cité de la Santé de Laval
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
London : London Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Montreal : Maisonneuve-Rosemont Hospital Research Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Sudbury : Northeast Cancer Centre of Health Sciences North, Health Sciences North
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Thunder Bay : Thunder Bay Regional Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Vancouver : British Columbia Cancer Agency - Vancouver Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Toronto : Princess Margaret Hospital
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
Finland
Helsinki : Department of Oncology, Helsinki University Central Hospital
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Germany
Germany : University of Heidelberg Medical Center
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
Korea, Republic of
Jung-gu Daejeon : Chungnam National University Hospital
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Netherlands
Amsterdam : Netherlands Cancer Institute
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
Nijmegen : University Medical Center Nijmegen st Radboud
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
United Kingdom
Papworth Everard : Papworth Hospital NHS Trust
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
